螯合剂增强肿瘤滞留与药代动力学特性:靶向神经降压素受体的64Cu标记放射性药物的开发
本研究合成了一系列不同丙胺连接臂长度和螯合剂的神经降压素受体拮抗剂,并用64Cu标记,在H1299肺癌模型中进行小动物PET/CT显像。结果显示肿瘤滞留受螯合剂强烈影响,先导化合物[64Cu]Cu-4b在4、24、48小时均表现高且持续的肿瘤摄取,肝脏摄取中等。患者组织样本免疫组化证实NTSR1表达升高。
要点
- 先导化合物[64Cu]Cu-4b在4、24、48小时肿瘤摄取分别为9.57±1.35、9.44±2.38、9.72±4.89%ID/g。
- 丙胺连接臂显著影响药物分布,[64Cu]Cu-4a背景更低且肝摄取大幅降低,但肿瘤摄取仅中度降低。
- [64Cu]Cu-4b不仅可用于检测肺癌NTSR1表达,与β发射体67Cu螯合后还有治疗NTSR阳性病灶的潜力。
核心结论
- [64Cu]Cu-4b因高且持续的肿瘤摄取和中等肝脏摄取被选为进一步评估的先导药物。
- [64Cu]Cu-4b不仅可高效检测肺癌NTSR1表达(用于诊断、患者筛选和治疗监测),与β发射体67Cu螯合后还有治疗NTSR阳性病灶的巨大潜力。
研究设计与样本
- 合成一系列不同丙胺连接臂长度和不同螯合剂的神经降压素受体拮抗剂,包括[64Cu]Cu-CB-TE2A-iPA-NRA([64Cu]Cu-4a-c,i=1,2,3)、[64Cu]Cu-NOTA-2PA-NRA([64Cu]Cu-4d)、[64Cu]Cu-DOTA-2PA-NRA([64Cu]Cu-4e,即[64Cu]Cu-3BP-227)和[64Cu]Cu-DOTA-VS-2PA-NRA([64Cu]Cu-4f)。
- 在H1299肺癌模型中进行系列小动物PET/CT,并用患者组织样本通过免疫组化确认NTSR1表达谱。
主要发现
- 大多数化合物的PET/CT显示突出肿瘤摄取和高肿瘤/背景对比,但肿瘤滞留受所用螯合剂强烈影响。
- 先前报道的4e的[64Cu]Cu标记衍生物显示初始高肿瘤摄取,但24小时肿瘤快速洗脱。
- 新开发的[64Cu]Cu-4d和[64Cu]Cu-4f在早期时间点显示良好肿瘤摄取和肿瘤/背景对比,但肿瘤滞留方面前景较差。
- 先导化合物[64Cu]Cu-4b在注射后4、24、48小时肿瘤摄取分别为9.57±1.35、9.44±2.38和9.72±4.89%ID/g。
- [64Cu]Cu-4b在注射后4、24、48小时肝脏摄取分别为11.97±3.85、9.80±3.63和7.72±4.68%ID/g,其他大多数器官摄取低。
关键数值与推荐
- 丙胺连接臂对药物分布有显著影响:与[64Cu]Cu-4b相比,[64Cu]Cu-4a背景更低(包括肝脏摄取大幅降低),但肿瘤摄取仅中度降低;[64Cu]Cu-4c肿瘤和肝脏摄取均增加。
- 患者组织样本中肿瘤NTSR1表达升高证实其临床相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accumulating evidence suggests that neurotensin (NTS) and neurotensin receptors (NTSRs) play key roles in lung cancer progression by triggering multiple oncogenic signaling pathways. This study aims to develop Cu-labeled neurotensin receptor 1 (NTSR1)-targeting agents with the potential for both imaging and therapeutic applications. METHOD: A series of neurotensin receptor antagonists (NRAs) with variable propylamine (PA) linker length and different chelators were synthesized, including [64Cu]Cu-CB-TE2A-iPA-NRA ([64Cu]Cu-4a-c, i = 1, 2, 3), [64Cu]Cu-NOTA-2PA-NRA ([64Cu]Cu-4d), [64Cu]Cu-DOTA-2PA-NRA ([64Cu]Cu-4e, also known as [64Cu]Cu-3BP-227), and [64Cu]Cu-DOTA-VS-2PA-NRA ([64Cu]Cu-4f). The series of small animal PET/CT were conducted in H1299 lung cancer model. The expression profile of NTSR1 was also confirmed by IHC using patient tissue samples. RESULTS: For most of the compounds studied, PET/CT showed prominent tumor uptake and high tumor-to-background contrast, but the tumor retention was strongly influenced by the chelators used. For previously reported 4e, [64Cu]Cu-labeled derivative showed initial high tumor uptake accompanied by rapid tumor washout at 24 h. The newly developed [64Cu]Cu-4d and [64Cu]Cu-4f demonstrated good tumor uptake and tumor-to-background contrast at early time points, but were less promising in tumor retention. In contrast, our lead compound [64Cu]Cu-4b demonstrated 9.57 ± 1.35, 9.44 ± 2.38 and 9.72 ± 4.89%ID/g tumor uptake at 4, 24, and 48 h p.i., respectively. Moderate liver uptake (11.97 ± 3.85, 9.80 ± 3.63, and 7.72 ± 4.68%ID/g at 4, 24, and 48 h p.i.) was observed with low uptake in most other organs. The PA linker was found to have a significant effect on drug distribution. Compared to [64Cu]Cu-4b, [64Cu]Cu-4a had a lower background, including a greatly reduced liver uptake, while the tumor uptake was only moderately reduced. Meanwhile, [64Cu]Cu-4c showed increased uptake in both the tumor and the liver. The clinical relevance of NTSR1 was also demonstrated by the elevated tumor expression in patient tissue samples. CONCLUSIONS: Through the side-by-side comparison, [64Cu]Cu-4b was identified as the lead agent for further evaluation based on its high and sustained tumor uptake and moderate liver uptake. It can not only be used to efficiently detect NTSR1 expression in lung cancer (for diagnosis, patient screening, and treatment monitoring), but also has the great potential to treat NTSR-positive lesions once chelating to the beta emitter 67Cu.
引用
- Zhang T, Ma X, Xu M, et al. Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor. Eur J Nucl Med Mol Imaging. 2024. PMID: 38771516. doi:10.1007/s00259-024-06754-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。